AnaptysBio, Inc. (ANAB) Reports Q4 Loss, Tops Revenue Estimates

Company Performance - AnaptysBio, Inc. reported a quarterly loss of $1.59 per share, which was better than the Zacks Consensus Estimate of a loss of $1.74, and compared to a loss of $0.93 per share a year ago, indicating an earnings surprise of 8.62% [1] - The company generated revenues of $9.01 million for the quarter ended December 2023, exceeding the Zacks Consensus Estimate by 174.29%, and up from $6.81 million in the same quarter last year [1] - Over the last four quarters, AnaptysBio has surpassed consensus EPS estimates three times, while it has topped consensus revenue estimates only once [1] Stock Performance - AnaptysBio shares have increased approximately 15.8% since the beginning of the year, outperforming the S&P 500's gain of 7.4% [2] - The current consensus EPS estimate for the upcoming quarter is -$1.57 on revenues of $3.51 million, and for the current fiscal year, it is -$6.46 on revenues of $14.89 million [4] Industry Outlook - The Medical - Biomedical and Genetics industry, to which AnaptysBio belongs, is currently ranked in the top 32% of over 250 Zacks industries, indicating a favorable outlook [5] - Another company in the same industry, TELA Bio, Inc., is expected to report a quarterly loss of $0.44 per share, reflecting a year-over-year change of +15.4%, with revenues anticipated to be $16.65 million, up 43.3% from the previous year [5][6]